In 2008, Sidney Taurel earned $8.22M in total compensation at Eli Lilly, including $1.08M salary, $2.33M bonus and $3.97M in stock. Led Eli Lilly as CEO for 9 years.
Compensation History
Annual executive compensation data for Sidney Taurel, including salary, bonuses, and stock awards.
Year
2008
Total Compensation
$8.22M
Salary
$1.08M
Bonus
$2.33M
Other
$839.43K
Salary
$1.08MBoard Justification
The compensation philosophy focuses on aligning executive pay with company performance, ensuring competitive pay to attract and retain talent, and maintaining a balance between short-term and long-term incentives.
Bonus
$2.33MBoard Justification
The bonus was based on the company's performance metrics, with a target bonus of 140% of salary, adjusted based on actual performance against established goals.
Other Compensation
$839.43KBoard Justification
Other compensation includes tax reimbursements and perquisites, including the use of corporate aircraft for business-related travel.
Restricted Stock
Board Justification
The vested stock represents performance awards granted for the year 2007, which were paid out in January 2008 and vested upon retirement.
Performance Metrics
Performance metrics included sales growth and adjusted earnings per share growth, which were critical in determining the cash bonus payouts.
Sidney Taurel
Ex-CEO of Eli Lilly
Education
MBA from Columbia University
Field of Expertise
Business & Management
Sector of Economy
Healthcare
Born
February 9, 1948 - 77 years ago
CEO of Eli Lilly for
9 years 8 months (Jul 1998 - Mar 2008)
Previous Experience
36-year Lilly employee
Other Eli Lilly CEOs
Holdings
Track Sidney Taurel's stock holdings and portfolio value over time.
Insider Trading
Sidney Taurel's recent stock transactions, purchases, and sales filed with the SEC.
No insider trades found for this CEO.
Rivals
Compare Sidney Taurel with competitor CEOs and industry peers.
Albert Bourla
CEO of Pfizer
2024 Compensation
Stock
$0.00
Salary
$1.80M
Bonus
$7.02M
Other
$996.06K
Total Holdings
$18.14M
Robert M. Davis
CEO of Merck & Co.
2024 Compensation
Stock
$18.10M
Salary
$1.62M
Bonus
$0.00
Other
$561.11K
Total Holdings
$43.45M
Joaquin Duato
CEO of Johnson & Johnson
2024 Compensation
Stock
$7.13M
Salary
$1.60M
Bonus
$3.22M
Other
$1.08M
Total Holdings
$1.09M
Stéphane Bancel
CEO of Moderna
2023 Compensation
Stock
$0.00
Salary
$1.58M
Bonus
$1.91M
Other
$1.07M
Total Holdings
$335.71M
Reshma Kewalramani
CEO of Vertex Pharmaceuticals
2022 Compensation
Stock
$10.64M
Salary
$1.40M
Bonus
$3.78M
Other
$43.06K
Total Holdings
$50.74M
Robert A. Bradway
CEO of Amgen
2024 Compensation
Stock
$0.00
Salary
$1.87M
Bonus
$0.00
Other
$714.33K
Total Holdings
$269.12M